


# Evaluation of Smartphone-Based Testing to Generate Exploratory Outcome Measures in a Phase 1 Parkinson's Disease Clinical Trial

Florian Lipsmeier, PhD,<sup>1</sup> Kirsten I. Taylor, PhD,<sup>1</sup> Timothy Kilchenmann, MSc,<sup>1</sup> Detlef Wolf, MSc,<sup>1</sup> Alf Scotland, MSc,<sup>1</sup> Jens Schjodt-Eriksen, PhD,<sup>1</sup> Wei-Yi Cheng, PhD,<sup>1</sup> Ignacio Fernandez-Garcia, PhD,<sup>1</sup> Juliane Siebourg-Polster, PhD,<sup>1</sup> Liping Jin, MD,<sup>1</sup> Jay Soto, BS,<sup>2</sup> Lynne Verselis, MA,<sup>1</sup> Frank Boess, PhD,<sup>1</sup> Martin Koller, MD,<sup>2</sup> Michael Grundman, MD,<sup>2,3</sup> Andreas U. Monsch, PhD,<sup>4</sup> Ronald B. Postuma, MD,<sup>5</sup> Anirvan Ghosh, PhD,<sup>1</sup> Thomas Kremer, PhD,<sup>1</sup> Christian Czech, PhD,<sup>1</sup> Christian Gossens, PhD <sup>1\*</sup> and Michael Lindemann, PhD<sup>1</sup>

<sup>1</sup>Roche Pharma Research and Early Development, pRED Informatics, Pharmaceutical Sciences, Clinical Pharmacology, and Neuroscience, Ophthalmology, and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland

<sup>2</sup>Prothena Biosciences Inc., South San Francisco, California, USA

<sup>3</sup>Global R&D Partners, LLC, San Diego, California, USA

<sup>4</sup>Felix Platter Hospital, University Center for Medicine of Aging, Memory Clinic, Basel, Switzerland; University of Basel, Faculty of Psychology, Basel, Switzerland

<sup>5</sup>Department of Neurology, McGill University, Montreal General Hospital, Montreal, Quebec, Canada

**ABSTRACT: Background:** Ubiquitous digital technologies such as smartphone sensors promise to fundamentally change biomedical research and treatment monitoring in neurological diseases such as PD, creating a new domain of digital biomarkers.

**Objectives:** The present study assessed the feasibility, reliability, and validity of smartphone-based digital biomarkers of PD in a clinical trial setting.

**Methods:** During a 6-month, phase 1b clinical trial with 44 Parkinson participants, and an independent, 45-day study in 35 age-matched healthy controls, participants completed six daily motor active tests (sustained phonation, rest tremor, postural tremor, finger-tapping, balance, and gait), then carried the smartphone during the day (passive monitoring), enabling assessment of, for

example, time spent walking and sit-to-stand transitions by gyroscopic and accelerometer data.

**Results:** Adherence was acceptable: Patients completed active testing on average 3.5 of 7 times/week. Sensor-based features showed moderate-to-excellent test-retest reliability (average intraclass correlation coefficient = 0.84). All active and passive features significantly differentiated PD from controls with  $P < 0.005$ . All active test features except sustained phonation were significantly related to corresponding International Parkinson and Movement Disorder Society–Sponsored UPRDS clinical severity ratings. On passive monitoring, time spent walking had a significant ( $P = 0.005$ ) relationship with average postural instability and gait disturbance scores. Of note, for all smartphone active and passive features except

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

\*Correspondence to: Dr. Christian Gossens, Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, 4070 Basel, Switzerland; E-mail: christian.gossens@roche.com

**Funding agencies:** The study was funded by F. Hoffmann-La Roche Ltd. and Prothena Biosciences Inc.

**Relevant conflicts of interest/financial disclosures:** Florian Lipsmeier is an employee of F. Hoffmann-La Roche AG, Basel, Switzerland. Kirsten I. Taylor is an employee of F. Hoffmann-La Roche AG, Basel, Switzerland. Timothy Kilchenmann is an employee of F. Hoffmann-La Roche AG, Basel, Switzerland. Detlef Wolf is an employee of F. Hoffmann-La Roche AG, Basel, Switzerland. Alf Scotland is a consultant for F. Hoffmann-La Roche AG, Basel, Switzerland. Jens Schjodt-Eriksen is a consultant for F. Hoffmann-La Roche AG, Basel, Switzerland. Wei-Yi Cheng is an employee of Roche TCRC Inc, New York, New York, USA. Ignacio Fernandez-Garcia is an employee of F. Hoffmann-La Roche AG, Basel, Switzerland. Juliane Siebourg-Polster is an employee of F. Hoffmann-La Roche AG, Basel, Switzerland. Liping Jin is an employee of Roche TCRC Inc, New York, New York, USA. Jay Soto is an employee

of and stockholder in Prothena Biosciences, San Francisco, California, USA. Lynne Verselis is an employee of Roche TCRC Inc, New York, New York, USA. Frank Boess is an employee of F. Hoffmann-La Roche AG, Basel, Switzerland. Martin Koller is an employee of and stockholder in Prothena Biosciences, San Francisco, California, USA. Michael Grundman is a consultant to Prothena Biosciences, San Francisco, California, USA. Andreas U. Monsch has grant support from F. Hoffmann-La Roche AG, Basel, Switzerland. Ronald B. Postuma is a consultant to F. Hoffmann-La Roche AG, Basel, Switzerland. Anirvan Ghosh is an employee of F. Hoffmann-La Roche AG, Basel, Switzerland. Thomas Kremer is an employee of F. Hoffmann-La Roche AG, Basel, Switzerland. Christian Czech is an employee of F. Hoffmann-La Roche AG, Basel, Switzerland. Christian Gossens is an employee of F. Hoffmann-La Roche AG, Basel, Switzerland. Michael Lindemann is a consultant to F. Hoffmann-La Roche AG, Basel, Switzerland.

Full financial disclosures and author roles may be found in the online version of this article.

**Received:** 8 December 2017; **Revised:** 15 February 2018; **Accepted:** 16 February 2018

**Published online 00 Month 2018 in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/mds.27376**

postural tremor, the monitoring procedure detected abnormalities even in those Parkinson participants scored as having no signs in the corresponding International Parkinson and Movement Disorder Society–Sponsored UPDRS items at the site visit.

**Conclusions:** These findings demonstrate the feasibility of smartphone-based digital biomarkers and indicate that smartphone-sensor technologies provide

reliable, valid, clinically meaningful, and highly sensitive phenotypic data in Parkinson's disease. © 2018 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.

**Key Words:** digital health; digital biomarkers; Parkinson's disease; clinical trial; remote patient monitoring

There is a growing anticipation that digital telemedicine technologies that measure Parkinson's disease (PD) signs will revolutionize clinical research and treatment monitoring.<sup>1</sup> These tools can provide frequent and mobile measurement of clinically relevant signals using electronic sensors that combine active (i.e., performing specific testing protocols) and passive protocols (i.e., monitoring movement during daily life), to quantify and/or predict health-related outcomes and support diagnostic processes. This approach promises to modernize clinical trial endpoints, improve clinical study design, and advance treatment monitoring.<sup>2,3</sup>

Digital biomarkers offer three main advantages compared with status quo in-clinic testing. First, by using objective multivariate sensor data with apps designed to measure clinical signs and symptoms, they can potentially quantify symptom severity with greater sensitivity and objectivity than clinical rating scales.<sup>4</sup> Second, with daily active tests and continuous passive monitoring, they enable even daily testing throughout longitudinal studies, a test frequency that was unthinkable just a few years ago. This promises greater measurement accuracy compared with data collected from clinic visits spaced weeks or months apart. This is particularly key for diseases with variable symptom severity such as PD. Last, with passive monitoring, the effects of PD on patients' daily lives can now be monitored and quantified in their usual home settings,<sup>5</sup> providing ecologically valid metrics to assess disease status and treatment effects.

Although numerous commercial digital biomarker devices are available,<sup>6–8</sup> common consumer technologies such as smartphones have the advantages of widespread availability, low cost, and high sensor quality. Several pilot research studies have successfully developed smartphone applications for PD.<sup>1,9–17</sup> In these pilot studies, proof of concept was typically established in a clinical setting by demonstrating significant differences between individuals with PD and healthy controls, and/or significant relationships between the sensor-based measures and the International Parkinson and Movement Disorder Society–Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) clinical gold standard.<sup>14,18–24</sup> For example, Kassavetis and colleagues<sup>18</sup> tested 14 PD participants

(mean disease duration = 3.7 years) with the MDS-UPDRS<sup>25</sup> and a custom Android application with the following active tests: resting, postural and kinetic tremor, pronation-supination, leg agility, and finger-tapping. For all tasks, the extracted sensor feature data significantly correlated with corresponding MDS-UPDRS<sup>25</sup> item scores (e.g., item 3.17, rest tremor amplitude).

Remote deployment of digital biomarker testing suites has been reported in far fewer studies. Arora and colleagues<sup>19</sup> deployed an Android smartphone to 10 individuals with PD (mean motor MDS-UPDRS score = 19.6 [standard deviation {SD} = 6.7]) and 10 controls, who performed four active tests (sustained phonation, gait, finger-tapping, and reaction time) four times daily for 1 month. Adherence was acceptable at 69%, and random forest machine-learning successfully discriminated PD participants from controls.<sup>27</sup> Using a similar approach on iPhones (Apple Inc., Cupertino, CA), the mPower app was launched with Apple's Research Kit platform (Apple Inc.) in March 2015<sup>28,29</sup> with surveys and the same tasks developed by Arora and colleagues.<sup>19</sup> In this study, 1,087 self-declared persons with PD and 5,581 self-declared persons without PD completed at least one active test or survey.<sup>28</sup> Adherence dropped sharply after the first few days post-download; 898 individuals contributed  $\geq 5$  days' data during the first 6 months following download. Data analysis of these results is pending. The Parkinson@home study<sup>26,30</sup> deployed the Fox Wearable Companion app to 953 participants in the Netherlands (13-week study) and North America (6-week study) to passively monitor behavior and rate the severity of selected symptoms. Adherence was 68% in the Netherlands and 62% in North America, and not affected by demographics, clinical characteristics, or attitude toward technology.<sup>26,30</sup> Further data analyses are pending. These preliminary findings represent major milestones in the development of digital biomarkers, and at the same time highlight the challenges yet to be overcome for the successful use of digital biomarker approaches in clinical research or patient monitoring, namely long-term adherence, consistency of sensor-derived feature data, and clinical validity of long-term, remote patient testing.

**TABLE 1.** Baseline demographic and clinical characteristics of the PD and control participants

Characteristic	PD	Controls	Difference (P Value)
N	43	35	
Age (yr)	57.5 ± 8.45	56.23 ± 7.83	0.5
Male Female	35 8	27 8	0.64
H & Y stage	1.91 ± 0.48	n/a	
Total MDS-UPDRS <sup>a</sup>	45.41 ± 17.22	3.17 ± 2.7	<0.001
MDS-UPDRS I	6.91 ± 4.71	1.80 ± 2.08	<0.001
MDS-UPDRS II	9.21 ± 6.10	0.23 ± 0.73	<0.001
MDS-UPDRS III	27.67 ± 11.22	1.14 ± 1.06	<0.001
MDS-UPDRS IV	1.63 ± 2.65	0 ± 0	<0.001
MoCA	26.86 ± 2.46	28.34 ± 1.35	0.001
Mean disease duration (yr)	3.51 ± 2.86	n/a	
Proportion of patients taking dopaminergic medication	81%	n/a	
Experiencing fluctuations (%) <sup>b</sup>	37% (30% experience at least a slight impact)		n/a
MDS-UPDRS-defined TD and PIGD PD subtypes	29 TD; 9 PIGD; 5 indeterminate	n/a	
Experiencing dyskinesia (%) <sup>c</sup>	9.3%	n/a	

Data are mean ± SD or proportions.

<sup>a</sup>Total MDS-UPDRS = MDS-UPDRS I + MDS-UPDRS II + MDS-UPDRS III.

<sup>b</sup>Proportion of patients with MDS-UPDRS 4.3 “time spent in the off state >0.”

<sup>c</sup>Proportion of patients with MDS-UPDRS 4.1 “time spent with dyskinesia >0.” A total of 1 PD had functional impact of dyskinesias, indicated by MDS-UPDRS 4.2 > 0.

TD, tremor dominant. n/a, not applicable.

The present study, which began in September 2015, determined the feasibility, reliability, and validity of digital biomarkers in a 6-month clinical trial of individuals with PD. These findings will provide a foundation for the future use of digital biomarkers in clinical trials and treatment monitoring of PD.

## Materials and Methods

We report data from two independent smartphone-based remote monitoring studies: a 6-month, phase 1b clinical drug trial of RG7935/PRX002 with 44 PD participants (NCT02157714); and a 6-week observational study of 35 age- and sex-matched controls. The effects of RG7935/PRX002 are not the focus of this study and are not reported here. Both studies were approved by the respective local ethics committees and written, informed consent was obtained from all participants (patient study: IRB00010809, H-35018, WOR1-14-143; control study: EKNZ-BASEC-2016-00596).

### Participants

Forty-four individuals with PD participated. Data from 1 patient was lost because of a lost phone. Thirty-five age-/sex-matched healthy controls were recruited from the Registry of Research-Interested Healthy Individuals at the Memory Clinic, University Center for Medicine of Aging Basel, Felix-Platter Hospital, Switzerland. All controls scored ≥ 26 points on the Montreal Cognitive Assessment (MoCA)<sup>32</sup> and were free of cardiovascular, neurological, or psychiatric conditions and had no first-degree relative with PD. The participants’ baseline characteristics (including PD subtype<sup>33</sup>) are described in Table 1.

### MDS-UPDRS


The MDS-UPDRS<sup>25</sup> (defined as gold standard for validation) was administered by trained raters (parts I and II) and physicians (part III) to PD participants during screening (study day -42 to -1) and days 8 and 64. Trained raters tested controls at baseline and day 42.

### Smartphone Testing

Procedures were identical for the PD and control studies. At initial in-clinic visits, all participants received a smartphone (Galaxy S3 mini; Samsung, Seoul, South Korea) with the Roche PD Mobile Application v1 (Roche, Basel, Switzerland) preinstalled, and a belt containing a pouch in which to carry the phone. Smartphones were locked-down (i.e., configured so patients could only run the Roche PD Mobile Application v1 and WiFi connection software). Training on the active tests was provided by site staff. Participants were instructed to complete the active tests at home once daily (ideally in the morning) and carry the phone with them throughout the day, recharging the phone overnight. The time of patients’ medication intake was not consistently collected. Battery charge lasted on average 7 hours per day.

### Active Tests

An Android custom application (Roche PD Mobile Application v1) was designed to measure cardinal PD motor signs (tremor, bradykinesia, and rigidity/postural instability) with inertial measurement unit sensor data (i.e., accelerometer, gyroscope, and magnetometer) and voice recorded with microphone (see Fig. 1).



**FIG. 1.** Screenshots of the smartphone application and workflow for the daily assessments. The smartphone (Galaxy S3 mini; Samsung, Seoul, South Korea) was provided with a single, preinstalled custom application (Roche PD Mobile Application v1; Roche, Basel, Switzerland). The application requested the completion of six active tests daily and subsequently recorded sensor data during daily living (“passive monitoring”), whereby participants were instructed to carry the smartphone in their trouser pocket, or a small bag around the waist.

The app included the following six active tests (see Supplementary Data available online for detailed instructions).

1. Sustained phonation: making a continuous “ahh” sound for as long as possible.
2. Rest tremor: seated, holding the phone in the palm of the hand resting on the lap.
3. Postural tremor: seated, holding the phone in their outstretched hand.
4. Finger-tapping: with the smartphone on a flat surface (e.g., table) alternately tapping two touchscreen buttons as regularly (i.e., not as quickly) as possible.
5. Balance task: standing still while having the smartphone in the trouser pocket or a specially-designed belt pouch.
6. Gait task: with the smartphone in the trouser pocket/belt pouch, walking 20 yards, turning around, and returning to the starting point.

Each task was preceded by a screen which named and explained the task. Participants pressed a button to start the task, after which a brief countdown appeared, then a start tone, followed by 30 seconds for the task concluding with a tone that signaled the end of the task. Participants were instructed to go outside to complete the gait task if they had no unobstructed 20-yard path to walk in their homes. The sustained phonation task recorded from the built-in microphone, and the finger-tapping test recorded all touchscreen events.

### Passive Monitoring

Participants were instructed to carry the phone with them throughout the day (e.g., in the trouser pocket

or provided belt pouch) enabling passive monitoring of daily activity via smartphone sensors.

### Data Transfer

The inertial measurement unit sensors sampled non-uniformly (accelerometer and gyroscope:  $66 \pm 10$  Hz; magnetometer:  $66 \pm 7$  Hz; microphone: 44.1 kHz), with comparable averages and SDs across phones. These time-stamped data were collected continuously while the smartphone battery was active (i.e., during active tests and passive monitoring). Participants received instructions on how to connect the smartphone to the Internet at home. If their home had no Internet, data were uploaded during site visits. All data were stored in encrypted files on the smartphone and sent by WiFi to a cloud storage facility each time the smartphone connected to the Internet.

### Data Processing

Data underwent quality control to ensure usability (e.g., sufficiently long sustained phonation; no walking during balance test). This resulted in the removal of 15% of sustained phonation data and 3% of all other active test data. Comparable amounts of data were discarded from PD and controls for each test. The following active test features were selected, based on previous literature and their relevancy to PD: (1) Sustained phonation: mel-frequency cepstral coefficient 2 (MFCC2)<sup>34,35</sup>; (2) Rest tremor: skewness<sup>36-39</sup>; (3) Postural tremor: total power<sup>40,41</sup>; (4) Finger tapping: intratap variability<sup>18,42</sup>; (5) Balance: mean velocity<sup>43-47</sup>; and (6) Gait: turn speed<sup>46,48-50</sup> (Table 2; see Supplementary Data available online and Cheng and colleagues<sup>51</sup> for additional details). For PD participants, feature data were averaged over the 2-week period

**TABLE 2.** Smartphone sensor features from each active and passive monitoring activity and corresponding MDS-UPDRS item(s) score, associated test-retest reliability, ability to detect control vs. PD differences, relationship with clinical symptom severity and ability to detect signs in PD participants clinically scored as having no signs

Activity	Sensor Feature and Unit	MDS-UPDRS Item(s)	Test-Retest Reliability of Sensor Feature	Controls vs. All PD		PD Participants: Relationship Between Active Test Feature and MDS-UPDRS Item(s) Score		Controls vs. PD Subgroup Rated as Having No Symptoms (MDS-UPDRS score = "0") at Respective Site Visit	
				t Value	P Value	t Value	P Value	t Value	P Value
Active tests			ICC						
Sustained phonation	MFCC2	2.1	0.82	-4.48	<0.001	-0.36	n.s.	-3.29	<0.001
Rest tremor	Skewness	3.18	0.90	7.6	<0.001	2.17	0.033	5.5	<0.001
Postural tremor	Power (m <sup>2</sup> /s <sup>3</sup> )	2.10	0.97	4.42	<0.001	2.61	0.011	0.83	n.s.
Finger tapping	Tap variability	2.5	0.64	8.46	<0.001	2.18	0.028	6.95	<0.001
Balance	Mean velocity (m/s)	3.13	0.80	8.29	<0.001	2.38	0.027	5.16	0.005
Gait	Turn speed (degree/s)	PIGD	0.88	-9.31	<0.001	-2.45	0.022	-8.25	<0.001
Passive monitoring			ICC						
Walking	Turn speed (degree/s)	Average PIGD	n/a	1,392	<0.001	-3.01	0.005	229	0.018
Sit-to-stand transitions	Sit-to-stand transitions (#/hour)	Average PIGD	n/a	1,087	0.005	-1.48	n.s.	250	n.s.
Walking vs. not walking	Activity ratio (%)	Average PIGD	n/a	1,392	<0.001	-2.02	0.055	321	0.003

Values for the active tests are t values from linear mixed-effects models that quantify the relationship between given MDS-UPDRS item(s) and the selected features and take repeated tests over time of the same subjects into account. Values for the passive monitoring activities are U values from the Mann-Whitney U test. MFCC2, mel-frequency cepstral coefficient 2; n/a, not applicable; n.s., not significant; STS, sit-to-stand/stand-to-sit transitions.

corresponding to the weeks before and after the site visits with the MDS-UPDRS. For controls, feature data were averaged over the first 2 study weeks and compared to baseline MDS-UPDRS.

A machine-learning algorithm based on a Human Activity Recognition (HAR) model<sup>52</sup> was used to classify passive monitoring accelerometer data into labeled activities (e.g., walking, climbing stairs, standing, and sitting).<sup>50</sup>

The HAR model was trained on two independent public data sets of everyday activity from normal individuals<sup>53,54</sup>; of these data, 90% were used to train the HAR model and 10% for model validation (see Cheng and colleagues<sup>51</sup> for details). To test the model's robustness and its appropriateness for the PD sample, two independent validations were performed: First, the model was tested on the validation data sample, where it reached 98% accuracy in distinguishing stationary from gait activities; second, the model's accuracy was tested on the unlabeled PD active test data, where it reached 99.5% and 96.9% accuracy when classifying PD balance and gait active test data, respectively. The HAR model was then applied to label human activities using a 5-second moving average, from which the following features were extracted: activity ratio<sup>50,55-57</sup> (i.e., time walking divided by total passive monitoring time), sit-to-stand transitions,<sup>45,50,58</sup> and turn speed<sup>46,48-50,59,60</sup> (Table 2).<sup>50</sup> One averaged summary score for each feature and participant was calculated over the whole observation period.

### Statistical Analyses

Adherence was quantified as the percentage of active tests completed for each study week (maximum: seven tests completed in 7 days; 100% adherence) per participant. Test-retest reliability of active test feature data from PD participants was assessed using the intraclass correlation coefficient (ICC) between the first and second 14-day testing periods.<sup>61</sup> Because of their non-normal distributions, Mann-Whitney U tests were used to compare passive monitoring features between PD and control participants.

Clinical validity of active test features was tested by relating each feature score, averaged over 2 weeks, to the corresponding MDS-UPDRS<sup>25</sup> item score (Table 1, columns 1-2 and 3). Thus, for each MDS-UPDRS item or subscale score for each patient, we compared an active test feature score comprised of the average performance estimate from all active test sessions conducted within the 2-week period surrounding (during the trial) or adjacent to (beginning and end of trial) the site visit at which the MDS-UPDRS was administered. The postural instability and gait difficulty (PIGD)<sup>33</sup> subscore (i.e., MDS-UPDRS 2.12 + 2.13 + 3.10 + 3.11 + 3.12) was selected as the comparator for the turn speed

feature. No direct comparator was available for the sustained phonation feature; therefore, speech (item 2.1) was used as the closest correlate. Linear mixed-effects models tested for significant relationships between each active test feature and the corresponding MDS-UPDRS item score, with individuals as random effects (to control for repeated MDS-UPDRS measurements per subject) and sex and age as covariates. Homoscedasticity was evident for all models. We report *t* values and associated *P* values from the models to quantify these relationships.

The ability of each active test feature to detect PD signs was tested by comparing feature scores between controls and all PD participants. Moreover, the ability to detect subtle or variable PD signs was tested by comparing features scores between controls and those PD participants whose corresponding MDS-UPDRS score or PIGD subscale score was 0 (Table 2, column 7). These analyses used linear mixed-effects models which covaried age and sex. Homoscedasticity was apparent for all models.

## Results

### Adherence


PD participants completed a total of 5,135 active tests, adhering to 61% of all possible test sessions during the 6-month trial period. Sixty-four percent of PD participants completed all active tests at least once every other day and 90% at least once every 4 days. Even in the last week of the 6-month study, PD participants completed all tests on average 3 of 7 days per week. A total of 1,542 active tests were completed by controls during their 6-week study, corresponding to an overall adherence of 100% in the shorter protocol. A total of 24,104 hours of passive monitoring data was collected from PD participants and 8,614 hours from controls.

### Reliability of Testing

Active test features demonstrated “excellent” (postural tremor) or “moderate to good” (all remaining features)<sup>62</sup> test-retest reliability (ICC; Table 2).

### Clinical Validity

Clinical validity of the active and passive sensor features was first evaluated by testing their ability to discriminate PD participants from controls. All active test and passive monitoring features significantly discriminated PD from controls (all  $P < 0.005$ ; Table 2). Compared to controls, PD participants manifested 34% less time performing gait-related activities (PD =  $0.1 \pm 0.05$ , controls =  $0.15 \pm 0.05$  proportion of time spent walking), 8.2% fewer sit-to-stand transitions (PD =  $1.67 \pm 0.23$ , controls =  $1.82 \pm 0.17$  per hour) and 18% slower > 90-degree turns (PD =  $50.3 \pm 8.2$ , controls =  $61.2 \pm 5.6$ ).



**FIG. 2.** Machine-learning algorithms applied to passive monitoring data revealed multiple aspects of significantly reduced everyday motor behavior in PD participants compared with controls. See Results (Reliability of Testing) for details.  $**P < 0.01$ ;  $***P < 0.001$ . C, control group.


Single participant data are shown in Figure 2, where each data point represents motor behavior averaged over the duration of the study, summarized with boxplots.

Clinical validity of the active test features was further assessed by comparing smartphone-based estimates of symptom severity (i.e., feature values) with corresponding MDS-UPDRS item or subscale scores (Fig. 3). These linear-effects mixed models revealed that all active test features, with the exception of sustained phonation, were significantly related to their corresponding MDS-UPDRS scores (Table 2; Fig. 3). For the passive monitoring features, only turn

speed was significantly related to average PIGD scores; both sit-to-stand transitions and activity ratio showed trends for a relationship with average PIGD (Table 2).

### Sensitivity for Undetected Manifestations

The ability of the active and passive test features to detect subtle or variable PD signs/symptoms was assessed through comparison of the feature scores of a subset of PD participants scored as having no signs/symptoms on the respective MDS-UPDRS item at the



**FIG. 3.** Active test feature scores aggregated over 2 weeks of in-home testing demonstrated case-control differences, significant relationships with clinical severity ratings, and significantly greater sensitivity compared with MDS-UPDRS item/subscale scores from site visits. The orange arrow indicates the statistical test for association of increased disease severity as to the selected MDS-UPDRS item with the digital biomarker feature, taking into account repeated measures per participant. The black square bracket indicates a comparison of the control group (C) with PD participants that are rated “0” for the corresponding MDS-UPDRS item.  $*P < 0.05$ ;  $**P < 0.01$ ;  $***P < 0.001$ . C, control group; MFCC2, mel-frequency cepstral coefficient 2; n.s., not significant.

site visit (i.e., with a MDS-UPDRS item score of 0) with controls. These analyses revealed that all active test features except postural tremor, and sit-to-stand transitions and activity ratio passive monitoring measures, detected significant PD-like abnormalities (compared with controls) in PD participants who demonstrated no signs on the corresponding MDS-UPDRS item(s) (Table 2; Fig. 3). It is important to note that postural tremor sensor measures were compared to patients' self-report of tremor interfering with daily life (MDS-UPDRS item 2.10); in this context, the negative result for postural tremor indicates that the sensor feature indeed accurately reflected patients' self-perceived symptom severity.

### Discussion

The present study is, to our knowledge, the first reported deployment of a digital biomarker approach in a clinical trial of PD. It provides an initial demonstration that use of commercially available smartphones for in-home active testing and passive monitoring in the home environment is feasible and provides reliable, clinically meaningful, and sensitive symptomatic data. All active and passive test features significantly differentiated controls from PD participants, and the magnitude of sensor-based features was significantly related to physician-administered MDS-UPDRS scores. Passive monitoring data revealed significantly reduced mobility in PD participants compared to controls. Finally, active tests could detect significant abnormalities even in PD participants who were rated as having no evidence of the corresponding sign on exam, suggesting that digital biomarkers may confer important sensitivity advantages. Together, these results indicate that a digital biomarker approach fulfills the prerequisites of acceptable adherence, reliability, validity, and sensitivity for use in long-term clinical trials and treatment monitoring.

The current protocol instructed PD participants to complete six daily active assessments over a period of 6 months. At the outset, it was unclear whether PD participants would adhere to this testing schedule (the testing procedure itself is short, approximately 5 minutes). We found that overall adherence to the active test protocol was 61% over 6 months, similar to a smaller-scale digital biomarker approach with four active tests performed four times daily for 1 month (69%<sup>19</sup>), and greater than what was observed with the general population deployment of mPower.<sup>28</sup> This demonstration of long-term adherence passes a crucial test for future digital biomarker use in long-term clinical trials and eventually for patient monitoring.

Beyond feasibility, the digital biomarker approach must produce sensor feature data of adequate reliability and validity to be used in research and clinical settings. Reliability analyses confirmed this to be the case: ICCs ranged from moderate (finger tapping; 0.64) to

excellent (postural tremor: 0.97) for all active tests. The clinical validity of the active and passive test features were confirmed in two independent sets of analyses. First, all sensor features exhibited clear disease-relevant signals by significantly differentiating PD participants from controls. Second, all but one sensor feature demonstrated a significant relationship between severity as estimated by the sensors and as rated by the physician. The exception was sustained phonation, where the MFCC2 feature was not significantly related to MDS-UPDRS Speech, item 2.1.<sup>25</sup> However, note that MFCC2 reflects the ratio between vocal tract resonance of the high, and vocal fold vibration of the low, Mel-frequency bands<sup>67</sup>; a parameter not specifically scored by MDS-UPDRS item 2.1.<sup>25</sup>

Daily sensor feature data appeared to be more sensitive at detecting subtle abnormalities than the less frequent physician ratings. Of note, significant motor impairments (compared to controls) were observed even in those PD participants rated as having no motor impairment on the corresponding MDS-UPDRS item(s) on five of the six feature variables (i.e., sustained phonation, resting tremor, finger tapping, walking speed, and turning speed). Only one (postural tremor) feature failed to detect this. However, this corresponding MDS-UPDRS item assessed the *self-perceived* interference of tremors on patients' daily functioning (and not postural tremor on examination). Patients who negated this phenomenon had sensor postural tremor scores on par with controls, thus indicating that the sensor accurately recapitulated patients' self-perception of tremor severity. For all MDS-UPDRS item(s) based on physician's ratings, the digital biomarker feature showed greater sensitivity, suggesting that a primary reason for the improved sensitivity is frequency of sampling. Clearly, frequent (i.e., daily) smartphone-based active testing has the advantage of sampling many more data points, increasing power to detect potentially subtle or variable PD motor signs, compared with much less frequent and time-limited clinical assessment. Moreover, PD participants' motor signs may be less severe in the activating presence of a physician than during daily life at home, leading to an underestimation of motor severity at clinic visits.<sup>68</sup> Taken together, these results indicate that a frequent and remote digital biomarker approach is more sensitive at detecting subtle and potentially variable motor impairments than MDS-UPDRS ratings at infrequent site visits.

There is a discontinuous mapping between motor performance during active, maximum capacity testing and patients' functional capacity in daily life.<sup>69</sup> For this reason, motor behavioral data acquired from continuous passive monitoring while patients go about their daily lives represent a critical complement to the clinical picture obtained from active or in-clinic testing. The machine-learning algorithms applied to



passive monitoring generated a HAR model which revealed that PD participants, even those scored as having no gait dysfunction at the site visits, were significantly less active than controls in several aspects of daily living: time spent performing gait-related activities, sit-stand transitions, and turn speed. Note that a cultural confound may partially explain these findings given that controls were recruited from Switzerland and PD participants from the United States. Critically, however, evaluating the PD sample alone revealed that turn speed was significantly related to PIGD scores, and gait activity showed a trend relationship with PIGD. The present findings are also in line with other studies measuring remote physical activity in PD, which were traditionally performed over shorter timeframes (i.e., 1 day to 1 week). These reported significantly less motor activity in PD compared to controls (e.g., fewer steps and shorter bouts of physical activity,<sup>48,70</sup>) some of which were related to disease severity<sup>71</sup> (for a review, see Block and colleagues<sup>5</sup>). Such insights may carry significant weight when assessing drug efficacy; that is, the ability of the therapy to improve patients' ability to perform everyday activities, which may be indirectly related to quality of life.<sup>72,73</sup>

Several limitations to this study exist. First, we did not control for participants' familiarity with digital technology including smartphones, which may affect active test performance or passive monitoring adherence. Second, note that ICCs calculated with mean data may lead to artificially heightened ICC values compared with ICCs calculated using individual data points. Third, whereas the applicability of our HAR model (generated using control data) to PD patient data was confirmed through successful categorization of PD active test data (i.e., data where activities being performed were known), feature extraction from PD passive monitoring may be improved through HAR models generated with combined control and patient data. In addition to these points, future research including the determination of appropriate feature cut-off values for healthy/diseased classifications, and prospective assessments to determine longitudinal relationships between digital biomarker features and clinical measures is warranted.

The promise of digital biomarkers to create a paradigm shift in biomedical research and clinical treatment monitoring is evident.<sup>3</sup> Our study demonstrates that digital biomarkers have now become feasible. Future research is needed to confirm whether digital biomarkers provide valid and fine-grained measures of disease severity and treatment response, enabling a better understanding of our patients' daily lives.

**Acknowledgments:** We thank all patients, their families, and the investigators who participated in this trial. Thanks also go to Meret Martin-Facklam for her contribution to this article. Editorial assistance

for the manuscript was provided by Watermeadow Medical, an Ashfield company, part of UDG Healthcare plc funded by F. Hoffmann-La Roche Ltd, Basel, Switzerland.

## References

1. Sanchez-Ferro A, Elshehabi M, Godinho C, et al. New methods for the assessment of Parkinson's disease (2005 to 2015): a systematic review. *Mov Disord* 2016;31:1283-1292.
2. Del Din S, Godfrey A, Galna B, Lord S, Rochester L. Free-living gait characteristics in ageing and Parkinson's disease: impact of environment and ambulatory bout length. *J Neuroeng Rehabil* 2016;13:46.
3. Dorsey ER, Papapetropoulos S, Xiong M, Kiebertz K. The first frontier: digital biomarkers for neurodegenerative disorders. *Digital Biomarkers* 2017;1:6-13.
4. Maetzler W, Domingos J, Srujies K, Ferreira JJ, Bloem BR. Quantitative wearable sensors for objective assessment of Parkinson's disease. *Mov Disord* 2013;28:1628-1637.
5. Block VA, Pitsch E, Tahir P, Cree BA, Allen DD, Gelfand JM. Remote physical activity monitoring in neurological disease: a systematic review. *PLoS One* 2016;11:e0154335.
6. Godinho C, Domingos J, Cunha G, et al. A systematic review of the characteristics and validity of monitoring technologies to assess Parkinson's disease. *J Neuroeng Rehabil* 2016;13:24.
7. Maetzler W, Nieuwhof F, Hasmann SE, Bloem BR. Emerging therapies for gait disability and balance impairment: promises and pitfalls. *Mov Disord* 2013;28:1576-1586.
8. Ossig C, Antonini A, Buhmann C, et al. Wearable sensor-based objective assessment of motor symptoms in Parkinson's disease. *J Neural Transm (Vienna)* 2016;123:57-64.
9. Adame RM, Al-Jawad A, Romanovas M, et al. TUG test instrumentation for Parkinson's disease patients using inertial sensors and dynamic time warping. *Biomed Tech* 2012;57:1071-1074.
10. Benninger F, Khlebtovsky A, Roditi Y, et al. Beneficial effect of levodopa therapy on stooped posture in Parkinson's disease. *Gait Posture* 2015;42:263-268.
11. Chien SL, Lin SZ, Liang CC, et al. The efficacy of quantitative gait analysis by the GAITRite system in evaluation of parkinsonian bradykinesia. *Parkinsonism Relat Disord* 2006;12:438-442.
12. Heldman DA, Espay AJ, LeWitt PA, Giuffrida JP. Clinician versus machine: reliability and responsiveness of motor endpoints in Parkinson's disease. *Parkinsonism Relat Disord* 2014;20:590-595.
13. Heldman DA, Giuffrida JP, Chen R, et al. The modified bradykinesia rating scale for Parkinson's disease: reliability and comparison with kinematic measures. *Mov Disord* 2011;26:1859-1863.
14. Lee CY, Kang SJ, Hong SK, Ma HI, Lee U, Kim YJ. A validation study of a smartphone-based finger tapping application for quantitative assessment of bradykinesia in Parkinson's disease. *PLoS One* 2016;11:e0158852.
15. Van Someren EJ, Pticek MD, Speelman JD, Schuurman PR, Esselink R, Swaab DF. New actigraph for long-term tremor recording. *Mov Disord* 2006;21:1136-1143.
16. Wang M, Wang B, Zou J, et al. A new quantitative evaluation method of parkinson's disease based on free spiral drawing. In: 3rd International Conference on Biomedical Engineering and Informatics (BMEI); Yantai, China, 2013. p. 694-698.
17. Woods AM, Nowostawski M, Franz EA, Purvis M. Parkinson's disease and essential tremor classification on mobile device. *Pervasive and Mobile Computing* 2014;13:1-12.
18. Kassavetis P, Tabish A, Saifee, et al. Developing a tool for remote digital assessment of Parkinson's disease. *Mov Disord Clin Pract* 2016;3:59-64.
19. Arora S, Venkataraman V, Zhan A, et al. Detecting and monitoring the symptoms of Parkinson's disease using smartphones: a pilot study. *Parkinsonism Relat Disord* 2015;21:650-653.
20. Printy BP, Renken LM, Herrmann JP, et al. Smartphone application for classification of motor impairment severity in Parkinson's disease. *Conf Proc IEEE Eng Med Biol Soc* 2014;2014:2686-2689.
21. Rehan Youssef A, Gumaa M. Validity and reliability of smartphone applications for clinical assessment of the neuromusculoskeletal system. *Expert Rev Med Devices* 2017;14:481-493.

22. Cancela J, Villanueva Mascato S, Gatsios D, et al. Monitoring of motor and non-motor symptoms of Parkinson's disease through a mHealth platform. *Conf Proc IEEE Eng Med Biol Soc* 2016;2016:663-666.
23. Arroyo-Gallego T, Ledesma-Carbayo MJ, Sanchez-Ferro A, et al. Detection of motor impairment in Parkinson's disease via mobile touchscreen typing. *IEEE Trans Biomed Eng* 2017;64:1994-2002.
24. Lee W, Evans A, Williams DR. Validation of a smartphone application measuring motor function in Parkinson's disease. *J Parkinsons Dis* 2016;6:371-382.
25. Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. *Mov Disord* 2008;23:2129-2170.
26. Silva de Lima AL, Hahn T, de Vries NM, et al. Large-scale wearable sensor deployment in Parkinson's patients: The Parkinson@Home Study Protocol. *JMIR Res Protoc* 2016;5:e172.
27. Chahine LM, Uribe L, Hogarth P, et al. Portable objective assessment of upper extremity motor function in Parkinson's disease. *Parkinsonism Relat Disord* 2017;43:61-66.
28. Bot BM, Suver C, Neto EC, et al. The mPower study, Parkinson disease mobile data collected using ResearchKit. *Sci Data* 2016;3:160011.
29. Wilbanks J, Friend SH. First, design for data sharing. *Nat Biotechnol* 2016;34:377-379.
30. Silva de Lima AL, Hahn T, Evers LJW, et al. Feasibility of large-scale deployment of multiple wearable sensors in Parkinson's disease. *PLoS One* 2017;12:e0189161.
31. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. *Neurology* 1967 17:427-442.
32. Nasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. *J Am Geriatr Soc* 2005;53:695-699.
33. Stebbins GT, Goetz CG, Burn DJ, Jankovic J, Khoo TK, Tilley BC. How to identify tremor dominant and postural instability/gait difficulty groups with the movement disorder society unified Parkinson's disease rating scale: comparison with the unified Parkinson's disease rating scale. *Mov Disord* 2013;28:668-670.
34. Benba A, Jilbab A, Hammouch A. Detecting patients with Parkinson's disease using Mel frequency cepstral coefficients and support vector machines. *Int J Elect Engineer Inform* 2015;7:297-307.
35. Kapoor T, R.K. S. Parkinson's disease diagnosis using Mel-frequency cepstral coefficients and vector quantization. *Int J Computer Appl* 2011;14:43-46.
36. Timmer J, Gantert C, Deuschl G, Honerkamp J. Characteristics of hand tremor time series. *Biol Cybern* 1993;70:75-80.
37. Deuschl G, Raethjen J, Baron R, Lindemann M, Wilms H, Krack P. The pathophysiology of parkinsonian tremor: a review. *J Neurol* 2000;247(Suppl 5):V33-V48.
38. Deuschl G, Raethjen J, Lindemann M, Krack P. The pathophysiology of tremor. *Muscle Nerve* 2001;24:716-735.
39. Haubenberger D, Abbruzzese G, Bain PG, et al. Transducer-based evaluation of tremor. *Mov Disord* 2016;31:1327-1336.
40. Vaillancourt DE, Newell KM. The dynamics of resting and postural tremor in Parkinson's disease. *Clin Neurophysiol* 2000;111:2046-2056.
41. Salarian A, Russmann H, Wider C, Burkhard PR, Vingerhoets FJ, Aminian K. Quantification of tremor and bradykinesia in Parkinson's disease using a novel ambulatory monitoring system. *IEEE Trans Biomed Eng* 2007;54:313-322.
42. Taylor Tavares AL, Jefferis GS, Koop M, et al. Quantitative measurements of alternating finger tapping in Parkinson's disease correlate with UPDRS motor disability and reveal the improvement in fine motor control from medication and deep brain stimulation. *Mov Disord* 2005;20:1286-1298.
43. Zijlstra A, Mancini M, Lindemann U, Chiari L, Zijlstra W. Sit-stand and stand-sit transitions in older adults and patients with Parkinson's disease: event detection based on motion sensors versus force plates. *J Neuroeng Rehabil* 2012;9:75.
44. Mayagoitia RE, Nene AV, Veltink PH. Accelerometer and rate gyroscope measurement of kinematics: an inexpensive alternative to optical motion analysis systems. *J Biomech* 2002;35:537-542.
45. Seimetz C, Tan D, Katayama R, Lockhart T. A comparison between methods of measuring postural stability: force plates versus accelerometers. *Biomed Sci Instrum* 2012;48:386-392.
46. Horak FB, Mancini M. Objective biomarkers of balance and gait for Parkinson's disease using body-worn sensors. *Mov Disord* 2013;28:1544-1551.
47. Mancini M, Carlson-Kuhta P, Zampieri C, Nutt JG, Chiari L, Horak FB. Postural sway as a marker of progression in Parkinson's disease: a pilot longitudinal study. *Gait Posture* 2012;36:471-476.
48. El-Gohary M, Pearson S, McNames J, et al. Continuous monitoring of turning in patients with movement disability. *Sensors (Basel)* 2013;14:356-369.
49. Salarian A, Zampieri C, Horak FB, Carlson-Kuhta P, Nutt JG, Aminian K. Analyzing 180 degrees turns using an inertial system reveals early signs of progression of Parkinson's disease. *Conf Proc IEEE Eng Med Biol Soc* 2009;2009:224-227.
50. Cheng WY, Scotland A, Lipsmeier F, et al. Human activity recognition from sensor-based large-scale continuous monitoring of Parkinson's disease patients. In: 2017 IEEE/ACM International Conference on Connected Health: Applications, Systems and Engineering Technologies (CHASE), Philadelphia, PA, 2017.
51. Cheng WYL, F. Scotland F, A. Creagh A, et al. Large-scale continuous mobility monitoring of Parkinson's disease patients using smartphones. *Proceedings from EAI MobiHealth 2017*. doi: 10.1109/LSC.2017.8268169.
52. Ordóñez FJ, Roggen D. Deep Convolutional and LSTM Recurrent Neural Networks for Multimodal Wearable Activity Recognition. *Sensors (Basel)* 2016;16:E115.
53. Stisen A, Blunck H, Bhattacharya S, et al., eds. Smart devices are different: Assessing and mitigating mobile sensing heterogeneities for activity recognition. In: *Proceedings of the 13th ACM Conference on Embedded Networked Sensor Systems*, 2015.
54. Weiss GM, Jeffrey W, Lockhart JW, eds. The impact of personalization on smartphone-based activity recognition. In: *AAAI Workshop on Activity Context Representation: Techniques and Languages*, 2012.
55. Crenna P, Carpinella I, Rabuffetti M, et al. The association between impaired turning and normal straight walking in Parkinson's disease. *Gait Posture* 2007;26:172-178.
56. Huxham F, Baker R, Morris ME, Ianssek R. Head and trunk rotation during walking turns in Parkinson's disease. *Mov Disord* 2008;23:1391-1397.
57. Mak MK, Patla A, Hui-Chan C. Sudden turn during walking is impaired in people with Parkinson's disease. *Exp Brain Res* 2008; 190:43-51.
58. Mayagoitia RE, Lotters JC, Veltink PH, Hermens H. Standing balance evaluation using a triaxial accelerometer. *Gait Posture* 2002; 16:55-59.
59. van Hilten JJ, Middelkoop HA, Kerkhof GA, Roos RA. A new approach in the assessment of motor activity in Parkinson's disease. *J Neurol Neurosurg Psychiatry* 1991;54:976-979.
60. White DK, Wagenaar RC, Del Olmo ME, Ellis TD. Test-retest reliability of 24 hours of activity monitoring in individuals with Parkinson's disease in home and community. *Neurorehabil Neural Repair* 2007;21:327-340.
61. Yen M, Lo LH. Examining test-retest reliability: an intra-class correlation approach. *Nurs Res* 2002;51:59-62.
62. Koo TK, Li MY. A guideline of selecting and reporting intraclass correlation coefficients for reliability research. *J Chiropr Med* 2016;15:155-163.
63. Sofuwa O, Nieuwboer A, Desloovere K, Willems AM, Chavret F, Jonkers I. Quantitative gait analysis in Parkinson's disease: comparison with a healthy control group. *Arch Phys Med Rehabil* 2005;86:1007-1013.
64. Morris ME, Ianssek R, Matyas TA, Summers JJ. The pathogenesis of gait hypokinesia in Parkinson's disease. *Brain* 1994;117(Pt 5): 1169-1181.
65. Nieuwboer A, De Weerd W, Dom R, Lesaffre E. A frequency and correlation analysis of motor deficits in Parkinson patients. *Disabil Rehabil* 1998;20:142-150.
66. van Lummel RC, Walgaard S, Maier AB, Ainsworth E, Beek PJ, van Dieën JH. The Instrumented Sit-to-Stand Test (iSTS) Has Greater Clinical Relevance than the Manually Recorded Sit-to-Stand Test in Older Adults. *PLoS One* 2016;11:e0157968.
67. Hlavnicka J, Cmejla R, Tykalova T, Sonka K, Ruzicka E, Rusz J. Automated analysis of connected speech reveals early biomarkers

- of Parkinson's disease in patients with rapid eye movement sleep behaviour disorder. *Sci Rep* 2017;7:12.
68. Broen MP, Marsman VA, Kuijf ML, Van Oostenbrugge RJ, van Os J, Leentjens AF. Unraveling the Relationship between Motor Symptoms, Affective States and Contextual Factors in Parkinson's Disease: A Feasibility Study of the Experience Sampling Method. *PLoS One* 2016;11:e0151195.
  69. Schenkman M, Ellis T, Christiansen C, et al. Profile of functional limitations and task performance among people with early- and middle-stage Parkinson disease. *Phys Ther* 2011;91:1339-1354.
  70. Mancini M, El-Gohary M, Pearson S, et al. Continuous monitoring of turning in Parkinson's disease: rehabilitation potential. *Neuro-Rehabilitation* 2015;37:3-10.
  71. Terashi H, Mitoma, H., Yoneyama, M., and Aizawa, H. Relationship between Amount of Daily Movement Measured by a Triaxial Accelerometer and Motor Symptoms in Patients with Parkinson's Disease. *Appl Sci* 2017;7:486.
  72. Motl RW, McAuley E. Pathways between physical activity and quality of life in adults with multiple sclerosis. *Health Psychol* 2009;28:682-689.
  73. Maetzler W, Klucken J, Horne M. A clinical view on the development of technology-based tools in managing Parkinson's disease. *Mov Disord* 2016;31:1263-1271.
  74. Innovation OU. Parkinson's Disease Questionnaire (PDQ-39 and PDQ-8) 2016. Available at: <https://innovation.ox.ac.uk/outcome-measures/parkinsons-disease-questionnaire-pdq-39-pdq-8/>.
  75. Takaya S. Differential diagnosis of parkinsonian syndromes using dopamine transporter and perfusion SPECT. *Parkinsonism Relat Disord* 2018;47:15-21.

## Supporting Data

Additional Supporting Information may be found in the online version of this article.